What is HC Wainwright’s Estimate for CTMX FY2026 Earnings?

CytomX Therapeutics, Inc. (NASDAQ:CTMX) – Investment analysts at HC Wainwright issued their FY2026 earnings estimates for CytomX Therapeutics in a research note issued to investors on Thursday, May 15th. HC Wainwright analyst M. Kapoor expects that the biotechnology company will post earnings per share of ($0.01) for the year. HC Wainwright has a “Buy” rating and a $5.00 price target on the stock. The consensus estimate for CytomX Therapeutics’ current full-year earnings is ($0.05) per share.

A number of other equities analysts have also commented on CTMX. Wedbush reaffirmed an “outperform” rating and issued a $6.00 price objective (up previously from $5.00) on shares of CytomX Therapeutics in a research note on Monday, May 12th. StockNews.com raised shares of CytomX Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, May 13th. Finally, Piper Sandler raised their price objective on shares of CytomX Therapeutics from $2.50 to $5.00 and gave the stock an “overweight” rating in a research note on Thursday.

CytomX Therapeutics Stock Performance

Shares of NASDAQ:CTMX opened at $2.03 on Friday. The company has a 50 day moving average price of $0.82 and a 200 day moving average price of $0.89. CytomX Therapeutics has a 1-year low of $0.40 and a 1-year high of $2.55. The stock has a market capitalization of $163.66 million, a price-to-earnings ratio of 11.94 and a beta of 1.11.

CytomX Therapeutics (NASDAQ:CTMX) last issued its earnings results on Monday, May 12th. The biotechnology company reported $0.27 earnings per share for the quarter, topping analysts’ consensus estimates of $0.18 by $0.09. The firm had revenue of $50.92 million during the quarter, compared to analysts’ expectations of $35.42 million. CytomX Therapeutics had a net margin of 10.96% and a negative return on equity of 41.47%. During the same period last year, the firm posted $0.17 earnings per share.

Hedge Funds Weigh In On CytomX Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. grew its holdings in shares of CytomX Therapeutics by 288,736.3% during the 4th quarter. JPMorgan Chase & Co. now owns 811,630 shares of the biotechnology company’s stock valued at $836,000 after acquiring an additional 811,349 shares in the last quarter. Renaissance Technologies LLC grew its holdings in shares of CytomX Therapeutics by 32.7% during the 4th quarter. Renaissance Technologies LLC now owns 1,346,800 shares of the biotechnology company’s stock valued at $1,387,000 after acquiring an additional 331,800 shares in the last quarter. Prudential Financial Inc. grew its holdings in shares of CytomX Therapeutics by 76.2% during the 4th quarter. Prudential Financial Inc. now owns 64,300 shares of the biotechnology company’s stock valued at $66,000 after acquiring an additional 27,800 shares in the last quarter. Schonfeld Strategic Advisors LLC grew its holdings in shares of CytomX Therapeutics by 13.9% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 1,380,800 shares of the biotechnology company’s stock valued at $1,422,000 after acquiring an additional 169,000 shares in the last quarter. Finally, Algert Global LLC purchased a new position in shares of CytomX Therapeutics during the 4th quarter valued at $35,000. Institutional investors and hedge funds own 67.77% of the company’s stock.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.